keyword
MENU ▼
Read by QxMD icon Read
search

HFREF

keyword
https://www.readbyqxmd.com/read/29782279/-response-predictors-for-physical-training-hfref-patients
#1
V L Galenko, T A Lelyavina, M Y Sitnikova
PURPOSE: To identify different types and possible predictors of physical rehabilitation (PR) response in reduced ejection fraction heart failure (HFrEF) patients, selected on the basis of achievement the lactate threshold during cardiopulmonary exercising test (CPET). METHODS: 64 patients, chronic heart failure (CHF) NYHA II-III functional class were included in our study. Mean age 54±12,5 years, body mass index (BMI) 26,5±6,4 kg/m2, ejection fraction (EF) 26,4±1,4 %, NYHA II: III (67 %: 33 % patients)...
2018: Kardiologiia
https://www.readbyqxmd.com/read/29781109/rate-pressure-product-and-the-components-of-heart-rate-and-systolic-blood-pressure-in-hospitalized-heart-failure-patients-with-preserved-ejection-fraction-insights-from-ascend-hf
#2
Amanda K Verma, Jie-Lena Sun, Adrian Hernandez, John R Teerlink, Phillip J Schulte, Justin Ezekowitz, Adriaan Voors, Randall Starling, Paul Armstrong, Christopher M O'Conner, Robert J Mentz
BACKGROUND: Heart rate (HR) and systolic blood pressure (SBP) are prognostic markers in heart failure with reduced ejection fraction (HFrEF). Their combination in rate-pressure product (RPP) as well as their role in heart failure with preserved ejection fraction (HFpEF) remains unclear. METHODS: We performed an analysis of ASCEND-HF (clinicaltrials.gov; NCT00476852), which studied 7141 patients with acute HF. HFpEF was defined as left ventricular ejection fraction (LVEF) ≥40%...
May 20, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/29779951/is-the-paradigm-hf-cohort-representative-of-the-real-world-heart-failure-patient-population
#3
Gustavo Rodrigues, António Tralhão, Carlos Aguiar, Pedro Freitas, António Ventosa, Miguel Mendes
INTRODUCTION: A new drug with prognostic impact on heart failure, sacubitril/valsartan, has been introduced in current guidelines. However, randomized trial results can be compromised by lack of representativeness. We aimed to assess the representativeness of the PARADIGM-HF trial in a real-world population of patients with heart failure. METHODS: We reviewed the records of 196 outpatients followed in a heart failure clinic between January 2013 and December 2014...
May 17, 2018: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://www.readbyqxmd.com/read/29777284/current-drug-therapy-for-heart-failure-with-reduced-ejection-fraction
#4
D Berliner, M Hallbaum, J Bauersachs
The prevalence of heart failure has been steadily increasing during the past few years, with a further increase predicted in the years to come. Without treatment, the syndrome of heart failure has a very poor prognosis. Advances in drug treatments and the consequent implementation of a guideline-recommended drug therapy have significantly improved the prognosis in heart failure with reduced ejection fraction (HFrEF). Besides angiotensin-converting enzyme (ACE) inhibitors (ACEi) or angiotensin receptor blockers, beta-blockers and diuretics treatment with mineralocorticoid receptor antagonists and ivabradine have become standard in the therapy of symptomatic patients with HFrEF...
May 18, 2018: Herz
https://www.readbyqxmd.com/read/29771478/the-reverse-remodeling-response-to-sacubitril-valsartan-therapy-in-heart-failure-with-reduced-ejection-fraction
#5
Pieter Martens, Hanne Beliën, Matthias Dupont, Pieter Vandervoort, Wilfried Mullens
BACKGROUND: Major classes of medical therapy for heart failure with reduced ejection fraction (HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan remains unstudied. METHODS: We performed a single-center, prospective assessor-blinded study to determine the reverse remodeling response of sacubitril/valsartan-therapy in HFrEF-patients with a class I-indication (New York heart Association [NYHA]-class II-IV, Left ventricular ejection fraction [LVEF]<35%, optimal dose with Renin-Angiotensin-System-Blocker [RAS-blocker])...
May 17, 2018: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/29765531/comparison-of-coronary-artery-bypass-grafting-and-percutaneous-coronary-intervention-in-patients-with-heart-failure-with-reduced-ejection-fraction-and-multivessel-coronary-artery-disease
#6
Michał Hawranek, Michal O Zembala, Mariusz Gasior, Tomasz Hrapkowicz, Łukasz Pyka, Daniel Cieśla, Marian Zembala
Aims: To compare coronary artery bypass grafting (CABG) with percutaneous coronary interventions (PCI) in patients with heart failure with reduced ejection fraction (HFrEF) and multivessel coronary artery disease. Methods: 1213 patients were selected from institutional databases, 761 and 452 in CABG and PCI group respectively. Only the subjects with left ventricle ejection fraction ≤ 35% and multivessel coronary artery disease were included to the study. The primary outcome measure was long-term all-cause death, the secondary outcomes were recurrent myocardial infarction, urgent repeat revascularization and stroke...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29763816/design-of-a-phase-3-trial-of-intracoronary-administration-of-human-adenovirus-5-encoding-human-adenylyl-cyclase-type-6-rt-100-gene-transfer-in-patients-with-heart-failure-with-reduced-left-ventricular-ejection-fraction-the-flourish-clinical-trial
#7
William F Penny, Timothy D Henry, Matthew W Watkins, Amit N Patel, H Kirk Hammond
The prognosis of patients with HFrEF remains poor despite the use of current medical and device therapies. Preclinical studies of HFrEF using IC delivery of RT-100, a replication deficient, E1/E3-deleted human adenovirus 5 encoding human AC6 was associated with favorable effects on LV function and remodeling. A recent multicenter, double-blind, placebo-controlled, phase 2 study demonstrated the safety of IC delivery of RT-100 in HFrEF patients and potential efficacy at the higher doses. This phase 2 dose finding study, which included doses not expected to be effective, identified a potential reduction in congestive heart failure admissions in the AC6-treated group one year after randomization...
April 6, 2018: American Heart Journal
https://www.readbyqxmd.com/read/29762842/the-role-of-commonly-used-clinical-indicators-in-the-diagnosis-of-acute-heart-failure
#8
X-L Wang, J-M Lei, Y Yuan, L Feng, Y Ning, Y-F Liu
OBJECTIVE: Acute heart failure (AHF) is one of the most commonly seen clinical cases, with a high rate of re-hospitalization and mortality. AHF can be divided into two categories based on the systolic function of the left ventricle, which are heart failure with reduced ejection fraction (HFREF) and heart failure with preserved ejection fraction (HFPEF). Pathogenesis and treatment of the two are quite different. In this article we attempted to explore the value of combined use of clinical and laboratory indicators in the differential diagnosis of AHFREF and AHFPEF...
April 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29762337/real-life-indications-to-ivabradine-treatment-for-heart-rate-optimization-in-patients-with-chronic-systolic-heart-failure
#9
Lara Tondi, Gabriele Fragasso, Roberto Spoladore, Giuseppe Pinto, Marco Gemma, Massimo Slavich, Cosmo Godino, Anna Salerno, Claudia Montanaro, Alberto Margonato
: Ivabradine is a selective and specific inhibitor of If current. With its pure negative chronotropic action, it is recommended by European Society of Cardiology and American College of Cardiology/American Heart Association guidelines in symptomatic heart failure patients (NYHA ≥ 2) with ejection fraction 35% or less, sinus rhythm and heart rate (HR) at least 70 bpm, despite maximally titrated β-blocker therapy. Data supporting this indication mainly derive from the SHIFT study, in which ivabradine reduced the combined endpoint of mortality and hospitalization, despite the fact that only 26% of patients enrolled were on optimal β-blocker doses...
May 11, 2018: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/29761362/pulmonary-hypertension-due-to-left-heart-disease-diagnostic-and-prognostic-value-of-ct-in-chronic-systolic-heart-failure
#10
Geoffrey C Colin, Bernhard L Gerber, Christophe de Meester de Ravenstein, David Byl, Anna Dietz, Michele Kamga, Agnes Pasquet, David Vancraeynest, Jean-Louis Vanoverschelde, Anne-Marie D'Hondt, Benoit Ghaye, Anne-Catherine Pouleur
OBJECTIVES: To evaluate the ability of chest computed tomography (CT) to predict pulmonary hypertension (PH) and outcome in chronic heart failure with reduced ejection fraction (HFrEF). METHODS: We reviewed 119 consecutive patients with HFrEF by CT, transthoracic echocardiography (TTE) and right heart catheterization (RHC). CT-derived pulmonary artery (PA) diameter and PA to ascending aorta diameter ratio (PA:A ratio), left atrial, right atrial, right ventricular (RV) and left ventricular volumes were correlated with RHC mean pulmonary arterial pressure (mPAP) ...
May 14, 2018: European Radiology
https://www.readbyqxmd.com/read/29754666/a-genotype-directed-comparative-effectiveness-trial-of-bucindolol-and-metoprolol-succinate-for-prevention-of-symptomatic-atrial-fibrillation-atrial-flutter-in-patients-with-heart-failure-rationale-and-design-of-the-genetic-af-trial
#11
Jonathan P Piccini, Stuart J Connolly, William T Abraham, Jeff S Healey, Benjamin A Steinberg, Hussein R Al-Khalidi, Patricia Dignacco, Dirk J van Veldhuisen, William H Sauer, Michel White, Stephen B Wilton, Inder S Anand, Christopher Dufton, Debra A Marshall, Ryan G Aleong, Gordon W Davis, Richard L Clark, Laura L Emery, Michael R Bristow
BACKGROUND: Few therapies are available for the safe and effective treatment of atrial fibrillation (AF) in patients with heart failure. Bucindolol is a non-selective beta-blocker with mild vasodilator activity previously found to have accentuated antiarrhythmic effects and increased efficacy for preventing heart failure events in patients homozygous for the major allele of the ADRB1 Arg389Gly polymorphism (ADRB1 Arg389Arg genotype). The safety and efficacy of bucindolol for the prevention of AF or atrial flutter (AFL) in these patients has not been proven in randomized trials...
May 2018: American Heart Journal
https://www.readbyqxmd.com/read/29754646/effect-of-carvedilol-vs-metoprolol-succinate-on-mortality-in-heart-failure-with-reduced-ejection-fraction
#12
Tarek Ajam, Samer Ajam, Srikant Devaraj, Kahee Mohammed, Stephen Sawada, Masoor Kamalesh
BACKGROUND: Beta blocker therapy is indicated in all patients with heart failure with reduced ejection fraction (HFrEF) as per current guidelines. The relative benefit of carvedilol to metoprolol succinate remains unknown. This study aimed to compare survival benefit of carvedilol to metoprolol succinate. METHODS: The VA's databases were queried to identify 114,745 patients diagnosed with HFrEF from 2007 to 2015 who were prescribed carvedilol and metoprolol succinate...
May 2018: American Heart Journal
https://www.readbyqxmd.com/read/29744528/device-therapy-in-heart-failure-with-reduced-ejection-fraction-cardiac-resynchronization-therapy-and-more
#13
D Duncker, C Veltmann
In patients with heart failure with reduced ejection fraction (HFrEF), optimal medical treatment includes beta-blockers, ACE inhibitors/angiotensinreceptor-neprilysin inhibitors (ARNI), mineralocorticoid receptor antagonists, and ivabradine when indicated. In device therapy of HFrEF, implantable cardioverter-defibrillators and cardiac resynchronization therapy (CRT) have been established for many years. CRT is the therapy of choice (class I indication) in symptomatic patients with HFrEF and a broad QRS complex with a left bundle branch block (LBBB) morphology...
May 9, 2018: Herz
https://www.readbyqxmd.com/read/29740701/characteristics-and-circadian-distribution-of-cardiac-arrhythmias-in-patients-with-heart-failure-and-sleep-disordered-breathing
#14
Hazem Omran, Thomas Bitter, Dieter Horstkotte, Olaf Oldenburg, Henrik Fox
BACKGROUND: Cardiac arrhythmias and sleep-disordered breathing (SDB) are common comorbidities in heart failure with reduced ejection fraction (HFrEF). However, understanding of the association between arrhythmias and SDB is poor. This study assessed the occurrence and circadian distribution of ventricular arrhythmias in HFrEF patients with and without SDB. METHODS: This retrospective analysis included HFrEF patients admitted for unattended overnight cardiorespiratory polygraphy and 24-h Holter-ECG recording...
May 8, 2018: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/29731345/metoprolol-vs-diltiazem-in-the-acute-management-of-atrial-fibrillation-in-patients-with-heart-failure-with-reduced-ejection-fraction
#15
RaeAnn Hirschy, Kimberly A Ackerbauer, Gary D Peksa, E Paul O'Donnell, Joshua M DeMott
OBJECTIVE: The objective of this study was to examine the effects of metoprolol versus diltiazem in the acute management of atrial fibrillation (AF) with rapid ventricular response (RVR) in patients with heart failure with reduced ejection fraction (HFrEF). METHODS: This retrospective cohort study of patients with HFrEF in AF with RVR receiving either intravenous push (IVP) doses of metoprolol or diltiazem was conducted between January 2012 and September 2016. The primary outcome was successful rate control within 30 min of medication administration, defined as a heart rate (HR) < 100 beats per minute or a HR reduction ≥ 20%...
April 27, 2018: American Journal of Emergency Medicine
https://www.readbyqxmd.com/read/29731121/sudden-death-after-hospitalization-for-heart-failure-with-reduced-ejection-fraction-from-the-everest-trial
#16
Muthiah Vaduganathan, Ravi B Patel, Robert J Mentz, Haris Subacius, Neal A Chatterjee, Stephen J Greene, Andrew P Ambrosy, Aldo P Maggioni, James E Udelson, Karl Swedberg, Marvin A Konstam, Christopher M O'Connor, Javed Butler, Mihai Gheorghiade, Faiez Zannad
Patients with chronic heart failure with reduced ejection fraction (HFrEF) benefit from medical and device therapies targeting sudden cardiac death (SCD). Contemporary estimates of SCD risk after hospitalization for heart failure are limited. We describe the incidence, timing, and clinical predictors of SCD after hospitalization for HFrEF (≤40%) in the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) trial. Multiple logistic regression analyses tested >30 baseline covariates (including treatment randomization, demographics, comorbid conditions, natriuretic peptides, ejection fraction, and medical and device therapies) to identify predictors of 1-year SCD...
April 11, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29731118/post-traumatic-stress-disorder-and-heart-failure-in-men-within-the-veteran-affairs-health-system
#17
Marat Fudim, Lukasz P Cerbin, Srikant Devaraj, Tarek Ajam, Sunil V Rao, Masoor Kamalesh
Patients with post-traumatic stress disorder (PTSD) are at risk of multiple co-morbidities and are more likely to develop incident heart failure with reduced ejection fraction (HFrEF). The relation of PTSD with clinical outcomes in HFrEF is not established. US veterans diagnosed with HFrEF from January 2007 to January 2015 and treated nationwide in the Veterans Affairs (VA) Health System were included in the study. Patients with HFrEF were identified through International Classification of Diseases, Ninth Revision (ICD-9) codes...
April 11, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29727039/microvascular-complications-in-diabetes-patients-with-heart-failure-and-reduced-ejection-fraction-insights-from-the-beta-blocker-evaluation-of-survival-trial
#18
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Li Shen, Matthew M Y Lee, Mark C Petrie, Lars Køber, John J V McMurray
AIMS: The role of microvascular complications in the risk conferred by diabetes in heart failure with reduced ejection fraction (HFrEF) is unknown. METHODS AND RESULTS: We studied 2707 HFrEF patients in the Beta-blocker Evaluation of Survival Trial (BEST), stratified into three groups: no diabetes and diabetes without or with microvascular complications (neuropathy, nephropathy, or retinopathy). The risks of the composite of cardiovascular death or heart failure hospitalization, and all-cause death, were studied using Cox regression analyses adjusted for other prognostic variables...
May 4, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29706429/heart-failure-subtypes-and-thromboembolic-risk-in-patients-with-atrial-fibrillation-the-prefer-in-af-hf-substudy
#19
Jolanta M Siller-Matula, Ladislav Pecen, Giuseppe Patti, Markus Lucerna, Paulus Kirchhof, Maciej Lesiak, Kurt Huber, Freek W A Verheugt, Irene M Lang, Giulia Renda, Renate B Schnabel, Rolf Wachter, Dipak Kotecha, Jean-Marc Sellal, Miklos Rohla, Fabrizio Ricci, Raffaele De Caterina
BACKGROUND AND OBJECTIVES: To assess thromboembolic and bleeding risks in patients with heart failure (HF) and atrial fibrillation (AF) according to HF type. METHODS: We analyzed 6170 AF patients from the Prevention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF), and categorized patients into: HF with reduced left-ventricular ejection fraction (HFrEF; LVEF < 40%); mid-range EF (HFmrEF; LVEF: 40-49%); lower preserved EF (HFLpEF; LVEF: 50-60%), higher preserved EF (HFHpEF; LVEF > 60%), and no HF...
April 22, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29705650/baroreflex-activation-therapy-for-the-treatment-of-heart-failure-with-reduced-ejection-fraction-in-patients-with-and-without-coronary-artery-disease
#20
Marcel Halbach, William T Abraham, Christian Butter, Anique Ducharme, Didier Klug, William C Little, Hannes Reuter, Jill E Schafer, Michele Senni, Vijay Swarup, Rolf Wachter, Fred A Weaver, Seth J Wilks, Michael R Zile, Jochen Müller-Ehmsen
BACKGROUND: In a randomized trial, baroreflex activation therapy (BAT) improved exercise capacity, quality of life and NT-proBNP in patients with heart failure with reduced ejection fraction (HFrEF). In view of different mechanisms underlying HFrEF, we performed a post-hoc subgroup analysis of efficacy and safety of BAT in patients with and without coronary artery disease (CAD). METHODS AND RESULTS: Patients with left ventricular ejection fraction <35% and NYHA Class III were randomized 1:1 to guideline-directed medical and device therapy alone or plus BAT...
April 21, 2018: International Journal of Cardiology
keyword
keyword
71067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"